Lung Cancer Online
Home Care Support Info Treatment Effects Tests Surviving Sites MedLit

home > treatment > sclc > extensive

SCLC Treatment - Extensive Disease

SCLC: Extensive disease - Recent MEDLINE Abstracts (PubMed)

Camptosar (irinotecan) Plus Cisplatin Increases Survival in Small Cell Lung Cancer (Doctor's Guide)
Reports that Camptosar (also known as irinotecan or CPT-11) in combination with cisplatin increased survival compared with the standard treatment (etoposide and cisplatin) for patients with extensive small cell lung cancer, according to a Phase III study presented at ASCO 2000. [5/00]

Four-Drug Regimen Enhances Responses and Increases Survival
v.9, no.11, Suppl. 6 Oncology News (November 2000)
Reports study results that found patients with extensive SCLC experienced better outcomes with a four-drug regimen of epirubicin (Ellence), cyclophosphamide (Cytoxan), etoposide (VePesid) and cisplatin (Platinol) than with the commonly used combination of etoposide and cisplatin. Registration required for free access. [11/00]


Feedback / Queries Disclaimer Advocacy - You Can Help

Copyright © 1999-2006, Lung Cancer Online Foundation
Last modified: 27-Apr-2011
Karen Parles, MLS Editor